A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma

OBJECTIVES: Based on single-arm trial data (BOLT), sonidegib was approved in the US and EU to treat locally advanced basal cell carcinomas (BCCs) ineligible for curative surgery or radiotherapy. Vismodegib, the other approved targeted therapy, also was assessed in a single-arm trial (ERIVANCE). We e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Skin Cancer
Autors principals: Odom, Dawn, Mladsi, Deirdre, Purser, Molly, Kaye, James A., Palaka, Eirini, Charter, Alina, Jensen, Jo Annah, Sellami, Dalila
Format: Artigo
Idioma:Inglês
Publicat: Hindawi 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457749/
https://ncbi.nlm.nih.gov/pubmed/28607774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/6121760
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars